research Central nervous system demyelination associated with tofacitinib use in alopecia areata: A case report and literature review
This case report describes a 23-year-old woman with alopecia areata who developed new central nervous system demyelination after starting tofacitinib therapy; while the drug was associated with this neurological event, causality is not confirmed. The demyelination was reversible upon stopping the medication and administering corticosteroids.




